Bradley Jones
Primary Care · Greenville, NCNPI 1568155018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,672, 3.3 times the $512 reported in 2023.
Across 214 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$548
- Novo Nordisk$533
- AbbVie$453
- AstraZeneca$389
- Pfizer$314
- GSK$244
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,572100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 52 | $548 |
| Novo Nordisk | 29 | $533 |
| AbbVie | 35 | $453 |
| AstraZeneca | 8 | $389 |
| Pfizer | 21 | $314 |
| GSK | 16 | $244 |
| Novartis | 10 | $168 |
| Sanofi-aventis U.S. LLC | 4 | $105 |
| Boehringer Ingelheim | 6 | $101 |
| Boston Scientific | 3 | $82 |
| Abbott | 3 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Abiomed | 1 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Astellas Pharma US Inc | 2 | $37 |
| Lilly USA, LLC | 2 | $34 |
| Dexcom, Inc. | 2 | $30 |
| Averitas Pharma Inc. | 1 | $29 |
| Tolmar, Inc. | 1 | $27 |
| Edwards Lifesciences | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,572 in reported general payments places this provider in the 85th percentile of 236 primary care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $38,143 |
| JardianceEmpagliflozin | 26 | $27,440 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $26,427 |
| Repatha SureclickEvolocumab | 31 | $24,305 |
| RybelsusSemaglutide | 16 | $18,212 |
| JanuviaSitagliptin Phosphate | 20 | $15,473 |
| EliquisApixaban | 17 | $13,937 |
| EntrestoSacubitril/Valsartan | 12 | $11,875 |
| BelsomraSuvorexant | 15 | $7,323 |
| SynthroidLevothyroxine Sodium | 12 | $1,739 |
| PaxlovidNirmatrelvir/Ritonavir | 14 | $1,379 |
| Gabapentin | 81 | $1,369 |
| Rosuvastatin Calcium | 171 | $1,365 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,244 |
| Valsartan | 46 | $1,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $533 | $56,35556 claims |
| Boehringer IngelheimJardiance | $101 | $27,44026 claims |
| GSKTrelegy Ellipta | $244 | $26,42739 claims |
| PfizerEliquis, Paxlovid | $314 | $15,31631 claims |
| NovartisEntresto | $168 | $11,87512 claims |
| AbbVieSynthroid | $453 | $1,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 236 primary care providers in North Carolina.
Other primary care in Greenville
- Kenzie Midgette DavisGreenville$6K
- Brianna JonesGreenville$2K
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.